ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2026
Steering Protein Generative Models at Test-Time for Guided AAV2 Capsid Design.
Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Recent advances in protein generative models have created new opportunities for protein engineering. However, a significant challenge remains in effectively steering these models to generate sequences with specific, desired functionalities, especially when these properties are defined by "black-box" or non-differentiable fitness functions. To address this, we present ProVADA+, a model-agnostic framework that guides pretrained generative models at testtime without costly retraining. Our approach introduces a reinforcement learning-based adaptive masking technique (MADA-DUCB) that significantly accelerates convergence. We demonstrate this framework on the challenging task of designing novel Adeno-Associated Virus 2 (AAV2) capsids. By coupling a ProteinMPNN generative prior with a fine-tuned AAV viability oracle, our method successfully navigates the rugged fitness landscape where unguided random mutagenesis is ineffective-with prior experiments showing as few as 0.3% of variants with six or more mutations are viable. In its final iterations, ProVADA generated a pool of novel candidates with a mean viral selection score of 2.72, consistently scoring highly viable variants while maintaining a diverse range of sequence similarity to the wildtype sequence. Our results show that ProVADA provides a powerful and efficient framework for accelerating the design of proteins with complex, user-defined properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.